Entropy Technologies’s Travere Therapeutics TVTX Stock Holding History

Entropy Technologies’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,464	Closed	-$697K	–	1231
2026 Q1	$697K	Buy	23,464 +1,263	+6%	+$37.8K	0.03%	514
2025 Q4	$848K	Buy	22,201 +5,408	+32%	+$176K	0.05%	424
2025 Q3	$401K	Buy	+16,793	New	+$316K	0.03%	580
2025 Q2	–	Sell	-14,592	Closed	-$261K	–	1024
2025 Q1	$261K	Buy	14,592 +2,292	+19%	+$46.5K	0.03%	569
2024 Q4	$214K	Buy	+12,300	New	+$218K	0.02%	625
2024 Q1	–	Sell	-27,838	Closed	-$250K	–	874
2023 Q4	$250K	Buy	+27,838	New	+$203K	0.05%	477

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Entropy Technologies's TVTX Position: Q2 2026 in Review

Entropy Technologies sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 23,464 shares — an estimated $697K sold.

Entropy Technologies first reported a position in TVTX in Q4 2023 and held it in 6 quarters. The position peaked at $848K in Q4 2025. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Entropy Technologies reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
Entropy Technologies sold 23,464 Travere Therapeutics shares in Q2 2026, an estimated $697K.
Entropy Technologies first reported a position in Travere Therapeutics in Q4 2023 and held it in 6 quarters.
Entropy Technologies's Travere Therapeutics position peaked at $848K in Q4 2025.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.